|
Source
|
Acute Attacks*
|
Hydrocele
|
Lymphoedema
|
Drug
|
Drug delivery strategy
|
Follow-up interval
|
|---|
|
Ciferri 1969 [170]
|
+
|
--
|
--
|
DEC
|
MDA
|
2 years
|
|
March 1960 [171]
|
+
|
+
|
+
|
DEC
|
MDA
|
10 years
|
|
Bernhard 2001 [169]
|
.
|
--
|
.
|
DEC
|
MDA, clinical trial
|
1 year
|
|
Partono 1989 [172]
|
+
|
.
|
+
|
DEC
|
MDA, selective
|
11 years
|
|
Beye 1952 [173]
|
--
|
--
|
--
|
DEC
|
MDA, selective
|
16 months
|
|
Simonsen 1995 [174]
|
.
|
--**
|
.
|
DEC
|
Selective
|
1 year
|
|
Kessel 1957 [175]
|
+
|
.
|
.
|
DEC
|
Selective
|
1 year
|
|
Fan 1995 [176]
|
.
|
--
|
--
|
DEC
|
Salt
|
16–19 years
|
|
Meyrowitch 1996 [177]
|
.
|
+
|
+
|
DEC
|
Salt
|
2 years
|
|
Meyrowitch 1998 [178]
|
.
|
+
|
.
|
DEC
|
Salt
|
4 years
|
|
Meyrowitch 2004 [179]
|
.
|
+¶
|
.
|
DEC
|
MDA, salt
|
4 years
|
|
Hewitt 1950 [180]
|
+
|
+¶
|
+¶
|
DEC
|
Clinical trial
|
8–14 months
|
|
Das 2003 [167]
|
.
|
.
|
--
|
DEC
|
Clinical trial
|
1 year
|
|
Kenney 1949 [181]
|
.
|
.
|
+
|
DEC
|
Clinical trial
|
1–3 months
|
|
Pani 1989 [51]
|
.
|
.
|
+‡
|
DEC
|
Clinical trial†
|
>1 year
|
|
Moore 1996 [16]
|
.
|
.
|
+
|
DEC
|
Case report
|
1 week-7 months
|
|
Bockarie 2002 [18]
|
.
|
+
|
+
|
DEC, DEC+IV
|
MDA
|
5 years
|
|
Dunyo 2000 [182]
|
.
|
--
|
--
|
IV + Alb
|
MDA
|
1 year
|
- * Acute dermatolymphangioadenitis and filarial lymphangitis were not distinguished in most studies
- ** 2 of 8 hydroceles resolved
- ¶Disease progression also observed
- ‡ Reductions seen primarily in patients with early-stage disease
- † Included other interventions, but improvement related to number of DEC doses
- + Decrease in size, incidence, or prevalence noted (not necessarily statistically significant)
- -- No decrease noted (or if noted, inconsistent or not considered significant by authors)
- . Not evaluated or extremely small numbers
- DEC Diethylcarbamazine
- IV Ivermectin
- Alb Albendazole
- MDA Mass drug administration using tablets
- Salt DEC-fortified salt
- Selective Treatment only of persons known to be infected or with clinical disease
